JW
Jayde Wang
CEO
ELEN MedTechEarly-stage medical technology
Australian medical technology
Reducing the diagnostic delay in endometriosis
ELEN MedTech is developing a handheld non-invasive diagnostic platform aimed at improving the early detection of superficial peritoneal endometriosis (SPE).
Our goal is to support clinicians with additional bedside information that may help reduce diagnostic delay and reliance on invasive procedures.
Focus Area
Superficial peritoneal endometriosis
Modality
Advanced non-invasive sensing and intelligent software
Stage
Early-stage medtech developing towards clinical validation
Rethinking diagnostic pathways
Today, many people with endometriosis wait years for a diagnosis, often culminating in invasive surgery. ELEN is exploring how non-invasive, bedside sensing could support more timely and informed clinical decisions.
- Intended setting
- Gynaecology and women's health clinics, hospitals
- Regions of focus
- Australia and the United States
The ELEN diagnostic platform is under development and is not yet approved for clinical use or available for purchase.
The diagnostic challenge in endometriosis
Endometriosis imposes a significant burden on individuals, health systems, and economies. Superficial peritoneal endometriosis (SPE) is a common form of endometriosis and remains difficult to detect with current imaging and diagnostic approaches. SPE is understood to represent a substantial proportion of endometriosis cases, contributing to underdiagnosis and delayed treatment.
- High prevalence
1 in 7
women are affected by endometriosis.
- Prolonged time to diagnosis
7 years
is the average time from symptom onset to diagnosis.
- Superficial peritoneal disease
- Superficial peritoneal endometriosis (SPE) is difficult to visualise and characterise with existing imaging, contributing to underdiagnosis and delayed treatment.
- Reliance on invasive surgery
- For many patients, confirmation of endometriosis still depends on laparoscopic surgery, carrying procedural risks and resource constraints.
A handheld diagnostic platform in development
ELEN MedTech is developing a handheld non-invasive diagnostic platform designed to support clinicians in the earlier identification of superficial peritoneal endometriosis (SPE).
- Combining advanced non-invasive sensing with intelligent software and computer vision concepts.
- Intended to integrate into existing gynaecology and women's health workflows in clinics and hospitals.
- Designed to provide clinicians with additional, non-invasive information at the bedside to inform diagnostic pathways.
The ELEN diagnostic platform is currently under development. It is not yet approved by regulatory authorities and is not available for clinical use or purchase.
Conceptual workflow
- 1
Point-of-care handheld assessment
A clinician uses the handheld device at the point of care, aligned with existing examination pathways.
- 2
Signal acquisition and intelligent analysis
Non-invasive, signal-based sensing captures data which is then processed by software and computer vision algorithms under development.
- 3
Clinically-oriented decision support
The intended output is a clear, interpretable signal to support earlier consideration of endometriosis and potentially reduce reliance on invasive procedures where appropriate.
Clinical insight and early validation
ELEN MedTech is engaging with clinicians across gynaecology and women's health to understand unmet needs in the diagnosis of superficial peritoneal endometriosis.
- Structured interviews and discussions with gynaecologists, sonographers, and pelvic pain specialists.
- Consistent feedback highlighting the need for more accessible, non-invasive tools to support earlier diagnosis.
- Strong interest from clinicians in both Australia and the United States in novel diagnostic approaches.
Building towards clinical evidence
As an early-stage medical technology company, ELEN is focused on robust clinical validation and clear regulatory pathways from the outset.
- Defining study designs to evaluate diagnostic performance in collaboration with clinical partners.
- Mapping potential regulatory pathways in Australia and the United States, including TGA and FDA considerations.
- Prioritising safety, data integrity, and clinician usability in product development.
Any future clinical use would be subject to successful trials and relevant regulatory approvals.
Market opportunity in women's health diagnostics
Clinics and hospitals in Australia and the United States are seeking scalable ways to address growing demand for women's health services, particularly in conditions with complex and delayed diagnostic pathways such as endometriosis.
High system burden
Repeated imaging, specialist referrals, and surgical procedures contribute to substantial direct and indirect costs for health systems and patients.
Demand for non-invasive tools
Clinicians are increasingly seeking bedside, non-invasive technologies that can complement existing imaging and support earlier decision-making.
Focused, scalable deployment
An effective diagnostic adjunct for superficial peritoneal endometriosis could be deployed across specialist clinics and hospital networks, with clear pathways for training and support.
Any future market access would depend on achieving positive clinical evidence, regulatory approvals, and alignment with reimbursement and procurement frameworks in each jurisdiction.
Team
ELEN MedTech brings together experience across operations, product, finance, and clinical practice to build a medically rigorous, commercially viable platform.
FG
Fernando Gargollo
COO
RA
Ryan Armin
CFO
CJ
Charlotte Jones
Head of Product
CT
Charlotte Thomas
Head of Clinical
Contact
For investor, clinical collaboration, or partnership enquiries, please contact the ELEN MedTech team.
Nothing on this site constitutes medical, financial, or legal advice. Any future clinical use of ELEN MedTech products would be subject to regulatory approval and appropriate clinical evaluation.